Open communication ensures your safety from the very first step
Diabetes 56(6):15511558
They convert glucose, amino acids and fats into energy
To use them, youll need to reach out to our support team at [email protected] and request that your credits be applied to your next renewal
In November 2025, the administration announced that Medicare will begin covering anti-obesity medications starting in 2026 as part of negotiated pricing agreements with manufacturers

Theoretical potential benefits (currently unproven for rheumatoid arthritis and not studied at microdose levels): Possible anti-inflammatory effects through modulation of immune pathways Weight reduction, which may indirectly benefit joint symptoms in overweight patients Cardiovascular risk reduction, relevant given increased cardiovascular disease risk in rheumatoid arthritis (established in type 2 diabetes populations at therapeutic doses only) [28] Improved metabolic parameters in patients with concurrent metabolic syndrome Known adverse effects of GLP-1 receptor agonists at standard doses include: Gastrointestinal symptoms : nausea, vomiting, diarrhoea, constipation, and abdominal discomfort (very common, affecting more than 1 in 10 patients) Hypoglycaemia : particularly when used with other glucose-lowering medications Injection site reactions : erythema, pruritus, or nodules Pancreatitis : rare but serious, requiring immediate medical attention if severe abdominal pain develops Gallbladder disease : increased risk of cholelithiasis and cholecystitis Thyroid effects : thyroid C-cell tumours observed in rodents
